Sidharth Kerkar
Founder & Chief Executive Officer AllerGene AI Therapeutics
Sid is a Pharma/Biotech leader and cell therapy innovator behind the discovery of MAGE-A as a pan-cancer target and next-generation T cell engineering with IL-12, now pioneering in vivo gene engineering to treat and prevent life-threatening allergies and anaphylaxis.
Seminars
Thursday 30th July 2026
In Vivo mRNA-LNP CAR-T Cells Targeting Mast Cells for Mast Cell-Driven Diseases, Severe Allergies & Anaphylaxis
11:00 am
- Defining the unmet medical need that can be fulfilled with an in vivo CAR-T approach
- Ideal features necessary for a safe and effective mast cell target
- Design and function of novel mRNA-LNP CAR constructs targeting human mast cells
